Trial Profile
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Cisplatin
- Indications Germ cell cancer
- Focus Adverse reactions
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
- 05 Aug 2019 Status changed from suspended to active, no longer recruiting.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology (data cut off December 1st 2017).